MK-5172: Phase II data

The double-blind, dose-ranging, placebo-controlled Phase II PN038 trial in 87 treatment-naïve, non-cirrhotic patients with HCV genotype 1 infection showed that once-daily MK-5172 plus peginterferon alfa-2b and ribavirin for 12 weeks led to an SVR 12 weeks after the end of treatment in 48.3% of patients at the 25 mg dose (n=29), 75% of patients at the 50 mg dose (n=28) and 86.7% of patients at the 100 mg dose (n=30). Additionally, SVR24 rates were 48.3% with the 25 mg MK-5172 dose, 75% with the 50 mg MK-5172 dose and 83.3% with the 100 mg MK-5172 dose. The most common adverse events reported were fatigue, headache, nausea and reduced appetite. Data were presented at the European Association for the Study of the Liver meeting in London. ...